Legend Biotech Corporation (LEGN) Morgan Stanley 23rd Annual Global Healthcare Transcript

Strategic Priorities - The company aims to achieve operational breakeven on CARVYKTI by the end of this year and profitability by 2026 [1] - Maximizing the market potential for CARVYKTI is identified as the top strategic priority [2] Clinical Data and Market Potential - Recent data presented at ASCO indicates that up to one-third of patients in the CARTITUDE-1 study, who are heavily pretreated, can achieve a 5-year treatment-free cancer remission [2] - This data is considered unprecedented in the context of multiple myeloma, which has historically been viewed as an incurable cancer [2] - The concept of a "functional cure" is being discussed among some doctors regarding the treatment outcomes for these patients [2]